Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL, including monoclonal antibodies to CD19 (Amgen’s Blincyto) and CD22 (Pfizer’s Besponsa); and the first chimeric antigen receptor (CAR) T-cells for relapsed/refractory pediatric and young adult ALL patients, namely Novartis’ Kymriah. Nonetheless, chemotherapies are highly effective and remain the backbone of frontline ALL treatment. New targeted therapies in development, including novel kinase inhibitors, proteasome inhibitors, and immunomodulatory agents hold promise of providing ALL patients additional treatment options, but will need to be incorporated into the current algorithm.

Questions Answered:

  • What is the size of the U.S. and EU5ALL patient populations, and how will drug treatment rates change over a 10-year period? What are the drug-treatable populations of most commercial interest?
  •  What is the current medical practice and management for ALL in the markets under study? What are interviewed experts’ insights on CAR T-cells and how are they being incorporated into the treatment algorithm?
  • What clinical needs remain unfulfilled? How could new emerging therapies fulfill those unmet needs?
  •  How has the entry of biosimilar rituximab in the EU5 and the generic entry of imatinib in the U.S. and EU5 impacted the ALL market?


Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Six country-specific interviews with thought leaders (medical oncologist-hematologists).

Epidemiology: Diagnosed incident cases of ALL subpopulations; clinical and market-relevant drug-treatable populations.

Population segments in market forecast: First-line adult and pediatric ALL; relapsed/refractory adult and pediatric ALL.

Emerging therapies: Phase III: 3 drugs; Phase II: 2 drugs.

Product Description: Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Commercial Outlook
      • Key Findings
      • Drivers and Constraints
        • What Factors Are Driving Sales in Acute Lymphoblastic Leukemia?
        • What Factors Are Constraining Sales in Acute Lymphoblastic Leukemia?
      • Drug-Class-Specific Trends
        • Increasing Adoption of Immunotherapies
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Disease Pathophysiology
      • Disease Classification
        • WHO Disease Classification
        • Prognostic Factors
        • Risk Classification of Acute Lymphoblastic Leukemia
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Age Distribution of Diagnosed Incident Cases
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment Overview
      • Key Findings
      • Diagnosis
        • Treatment Providers and Referral Patterns
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Kinase Inhibitors
        • Monoclonal Antibodies
        • Purine Nucleoside Analogues
        • Chemotherapy and New Formulations
        • Chimeric Antigen Receptor T-Cell Therapies
      • Medical Practice
        • Newly Diagnosed Acute Lymphoblastic Leukemia
        • Relapsed/Refractory Acute Lymphoblastic Leukemia
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Acute Lymphoblastic Leukemia
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Acute Lymphoblastic Leukemia
        • Chimeric Antigen Receptor T-Cell Therapies
        • Monoclonal Antibodies
        • Small-Molecule Kinase Inhibitors
        • Proteasome Inhibitors
        • Branded Chemotherapies and New Formulations
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Acute Lymphoblastic Leukemia
      • Orphan-Drug Designation
        • Orphan Drug Provisions: United States
        • Orphan Drug Provisions: Europe
    • Access & Reimbursement Overview
      • Looking for More?
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Acute Lymphoblastic Leukemia Bibliography

Author(s): Amy Yip, PhD

Amy Yip, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Yip worked as an analyst at GlobalData where she worked on a number of disease reports within Healthcare and Pharmaceuticals, with a particular focus on oncology. Dr. Yip obtained her doctorate in molecular medicine at the Liggins Institute, University of Auckland, where she investigated the impact of aberrant neurotrophic factor expression on hormone signaling pathways in breast cancer cells. Dr. Yip also holds a BSc (Hons) degree, with first class honors in biomedical science, awarded by the University of Auckland, and has previously worked with Novartis in their New Zealand office.